Commentary

Video

Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

Author(s):

David B. Zhen, MDSamuel Cytryn, MD

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Related Videos
Sergio A. Giralt, MD
Rahul Banerjee, MD, FACP
Chih-Yi Liao, MD
Mazyar Shadman, MD, MPH
Anthony B. El-Khoueiry, MD
Craig E. Devoe, MD, MS
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Ryan Hood, BA, MD/MPH student, University of Miami Miller School of Medicine
Related Content
Adam E. Singer, MD, PhD, of UCLA Health
September 12th 2024

Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
September 5th 2024

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

FDA
September 5th 2024

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

Solange Peters, MD, PhD
September 4th 2024

Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC